This database contains 22 studies, archived under the term: "Fronto Temporal (also known as Pick’s Disease)"
Click here to filter this large number of results.
Memantine in behavioral variant frontotemporal dementia: negative results
Vercelletto, Martine,
Boutoleau-Bretonnière, Claire,
Volteau, Christelle,
Puel, Michèle,
Auriacombe, Sophie,
Sarazin, Marie,
Michel, Bernard-François,
Couratier, Philippe,
Thomas-Antérion, Catherine,
Verpillat, Patrice,
Gabelle, Audrey,
Golfier, Véronique,
Cerato, Evelyne,
Lacomblez, Lucette
We tested the efficacy and tolerability of one-year treatment with memantine (10 mg bid) in behavioral variant frontotemporal dementia (bvFTD). BvFTD patients aged 45 to 75 years, with a Mini-Mental Status Examination (MMSE) score ≥19, were enrolled in a national, randomized, double-blind, placebo-controlled (DBPC), Phase II trial. The primary endpoint was the CIBIC-Plus (Clinician’s Interview-Based […]
The most common type of FTLD-FUS (aFTLD-U) is associated with a distinct clinical form of frontotemporal dementia but is not related to mutations in the FUS gene
Snowden, Julie S.,
Hu, Quan,
Rollinson, Sara,
Halliwell, Nicola,
Robinson, Andrew,
Davidson, Yvonne S.,
Momeni, Parastoo,
Baborie, Atik,
Griffiths, Timothy D.,
Jaros, Evelyn,
Perry, Robert H.,
Richardson, Anna,
Pickering-Brown, Stuart M.,
Neary, David,
Mann, David M. A.
Frontotemporal lobar degeneration (FTLD) is clinically, pathologically and genetically heterogeneous. Recent descriptions of a pathological sub-type that is ubiquitin positive, TDP-43 negative and immunostains positive for the Fused in Sarcoma protein (FUS) raises the question whether it is associated with a distinct clinical phenotype identifiable on clinical grounds, and whether mutations in the Fused in […]
Chromosome 9p21 in sporadic amyotrophic lateral sclerosis in the UK and seven other countries: a genome-wide association study
Shatunov, Aleksey,
Mok, Kin,
Newhouse, Stephen,
Weale, Michael E,
Smith, Bradley,
Vance, Caroline,
Johnson, Lauren,
Veldink, Jan H,
van Es, Michael A,
van den Berg, Leonard H.,
Robberecht, Wim,
Van Damme, Philip,
Hardiman, Orla,
Farmer, Anne E,
Lewis, Cathryn M,
Butler, Amy W,
Abel, Olubunmi,
Andersen, Peter M,
Fogh, Isabella,
Silani, Vincenzo,
Chiò, Adriano,
Traynor, Bryan J,
Melki, Judith,
Meininger, Vincent,
Landers, John E,
McGuffin, Peter,
Glass, Jonathan D,
Pall, Hardev,
Leigh, P Nigel,
Hardy, John,
Brown, Robert H,
Powell, John F,
Orrell, Richard W,
Morrison, Karen E,
Shaw, Pamela J,
Shaw, Christopher E,
Al-Chalabi, Ammar
Background: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease of motor neurons that results in progressive weakness and death from respiratory failure, commonly within about 3 years. Previous studies have shown association of a locus on chromosome 9p with ALS and linkage with ALS-frontotemporal dementia. We aimed to test whether this genomic region is also […]
The ALS-FTD-Q: a new screening tool for behavioral disturbances in ALS
Raaphorst, Joost,
Beeldman, Emma,
Schmand, Ben,
Berkhout, Joris,
Linssen, Wim H. J. P.,
van den Berg, Leonard H.,
Pijnenburg, Yolande A.,
Grupstra, Hepke F.,
Weikamp, Janneke G.,
Schelhaas, H. Jurgen,
Papma, Janne M.,
van Swieten, John C.,
de Visser, Marianne,
de Haan, Rob J.
Objective: The assessment of behavioral disturbances in amyotrophic lateral sclerosis (ALS) is important because of the overlap with the behavioral variant of frontotemporal dementia (ALS-bvFTD). Motor symptoms and dysarthria are not taken into account in currently used behavioral questionnaires. We examined the clinimetric properties of a new behavioral questionnaire for patients with ALS (Amyotrophic Lateral […]
Isolated theory of mind deficits and risk for frontotemporal dementia: A longitudinal pilot study
Pardini, M.,
Emberti Gialloreti, L.,
Mascolo, M.,
Benassi, F.,
Abate, L.,
Guida, S.,
Viani, E.,
Dal Monte, O.,
Schintu, S.,
Krueger, F.,
Cocito, L.
Objective: Recent data suggest that theory of mind (ToM) deficits represent an early symptom of the behavioural variant of frontotemporal dementia (bvFTD). However, longitudinal data on the natural history of subjects presenting with isolated ToM deficits are lacking. The aim of the study was to verify if isolated ToM deficits represent an at-risk state for […]
The effects of oxytocin on social cognition and behaviour in frontotemporal dementia
Jesso, S.,
Morlog, D.,
Ross, S.,
Pell, M. D.,
Pasternak, S. H.,
Mitchell, D. G. V.,
Kertesz, A.,
Finger, E. C.
Patients with behavioural variant frontotemporal dementia demonstrate abnormalities in behaviour and social cognition, including deficits in emotion recognition. Recent studies suggest that the neuropeptide oxytocin is an important mediator of social behaviour, enhancing prosocial behaviours and some aspects of emotion recognition across species. The objective of this study was to assess the effects of a […]
Object alternation: a novel probe of medial frontal function in frontotemporal dementia
Freedman, Morris,
Binns, Malcolm A.,
Black, Sandra E.,
Levine, Brian,
Miller, Bruce L.,
Ramirez, Joel,
Szilagyi, Gregory M.,
Scott, Christopher J. M.,
McNeely, Alicia A.,
Stuss, Donald T.
We studied behavioral variant frontotemporal dementia (bvFTD) using object alternation (OA) as a novel probe of cognition. This task was adopted from animal models and is sensitive to ventrolateral-orbitofrontal and medial frontal function in humans. OA was administered to bvFTD patients, normal controls, and a dementia control group with Alzheimer disease (AD). Two other frontal […]
Oxytocin for frontotemporal dementia: A randomized dose-finding study of safety and tolerability
Finger, E. C.,
MacKinley, J.,
Blair, M.,
Oliver, L. D.,
Jesso, S.,
Tartaglia, M. C.,
Borrie, M.,
Wells, J.,
Dziobek, I.,
Pasternak, S.,
Mitchell, D. G. V.,
Rankin, K.,
Kertesz, A.,
Boxer, A.
Objective: To determine the safety and tolerability of 3 doses of intranasal oxytocin (Syntocinon; Novartis, Bern, Switzerland) administered to patients with frontotemporal dementia (FTD). Methods: We conducted a randomized, parallel-group, double-blind, placebo-controlled study using a dose-escalation design to test 3 clinically feasible doses of intranasal oxytocin (24, 48, or 72 IU) administered twice daily for […]